<span item_type="fundamental" item_id="1ba3d38995686099de12d7b4d60ddb5a" counter_id="ST/US/ITRM" env="prod"></span><span item_type="announcement" item_id="582667228060975233" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 390 K.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.2, missing the estimate of USD -0.09.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -7.29 M.</p><p></p><h3>Segment Revenue</h3><ul><li><strong>Product Revenue, net</strong>: $390,000 for the three months ended September 30, 2025, compared to $0 for the same period in 2024. For the nine months ended September 30, 2025, product revenue was $390,000, compared to $0 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281557/itrm-20250930.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li><strong>Operating Loss</strong>: For the three months ended September 30, 2025, operating loss was -$7,731,000, compared to -$4,887,000 for the same period in 2024. For the nine months ended September 30, 2025, operating loss was -$16,970,000, compared to -$15,026,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281557/itrm-20250930.htm"></span></li><li><strong>Net Loss</strong>: For the three months ended September 30, 2025, net loss was -$8,979,000, compared to -$6,094,000 for the same period in 2024. For the nine months ended September 30, 2025, net loss was -$20,379,000, compared to -$18,192,000 in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281557/itrm-20250930.htm"></span></li></ul><h3>Cash Flow</h3><ul><li><strong>Net Cash Used in Operating Activities</strong>: -$15,258,000 for the nine months ended September 30, 2025, compared to -$22,514,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281557/itrm-20250930.htm"></span></li><li><strong>Net Cash Provided by Financing Activities</strong>: $2,164,000 for the nine months ended September 30, 2025, compared to $12,814,000 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281557/itrm-20250930.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li><strong>Amortization of Intangible Asset</strong>: $1,036,000 for the nine months ended September 30, 2025, compared to $0 for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281557/itrm-20250930.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: Iterum Therapeutics plc is focused on maximizing the commercial potential of ORLYNVAH™ in the U.S. and seeking marketing approval for other product candidates. The company expects modest sales of ORLYNVAH™ in 2025 during the early stages of commercialization efforts.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281557/itrm-20250930.htm"></span></li><li><strong>Non-Core Business</strong>: The company continues to engage in business development discussions with other companies to sell, license, or otherwise dispose of its rights to sulopenem.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281557/itrm-20250930.htm"></span></li><li><strong>Priority</strong>: The company is heavily dependent on the success of the commercial launch of ORLYNVAH™ in the United States and any failure to successfully commercialize ORLYNVAH™ will materially harm its business.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1659323/000119312525281557/itrm-20250930.htm"></span></li></ul>

Iterum Therap | 10-Q: FY2025 Q3 Revenue: USD 390 K